Volume 100, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



In 2016, there were more cases and deaths caused by malaria globally than in 2015. An effective vaccine would be an ideal additional tool for reducing malaria’s impact. Sanaria PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved (Pf) sporozoites (SPZ) has been well tolerated and safe in malaria-naïve and experienced adults in the United States and Mali and protective against controlled human malaria infection with Pf in the United States and field transmission of Pf in Mali, but had not been assessed in younger age groups. We, therefore, evaluated PfSPZ Vaccine in 93 Tanzanians aged 45 years to 6 months in a randomized, double-blind, normal saline placebo-controlled trial. There were no significant differences in adverse events between vaccinees and controls or between dosage regimens. Because all age groups received three doses of 9.0 × 10 PfSPZ of PfSPZ Vaccine, immune responses were compared at this dosage. Median antibody responses against Pf circumsporozoite protein and PfSPZ were highest in infants and lowest in adults. T-cell responses were highest in 6–10-year olds after one dose and 1–5-year olds after three doses; infants had no significant positive T-cell responses. The safety data were used to support initiation of trials in > 300 infants in Kenya and Equatorial Guinea. Because PfSPZ Vaccine–induced protection is thought to be mediated by T cells, the T-cell data suggest PfSPZ Vaccine may be more protective in children than in adults, whereas infants may not be immunologically mature enough to respond to the PfSPZ Vaccine immunization regimen assessed.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. GBD 2015 Mortality and Causes of Death Collaborators, 2016. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388: 14591544. [Google Scholar]
  2. World Health Organization, 2015. World Malaria Report 2015, Geneva, Switzerland: WHO. [Google Scholar]
  3. World Health Organization, 2018. World Malaria Report 2018. Geneva, Switzerland: WHO. [Google Scholar]
  4. Richie TL, 2015. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine 33: 74527461. [Google Scholar]
  5. RTS,S Clinical Trials Partnership, 2014. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 11: e1001685. [Google Scholar]
  6. European Medicines Agency, 2015. First Malaria Vaccine Receives Positive Scientific Opinion from EMA. Press Office, ed. EMA/CHMP/488348/2015. London, United Kingdom. [Google Scholar]
  7. World Health Organization, 2016. Malaria vaccine: WHO position paper-January 2016. Wkly Epidemiol Rec 91: 3351. [Google Scholar]
  8. World Health Organization, 2018. Malaria Vaccine Implementation Program – Progress Update. Available at: http://www.who.int/immunization/sage/meetings/2018/april/2_WHO_MalariaMVIPupdate_SAGE_Apr2018.pdf. Accessed August 8, 2018. [Google Scholar]
  9. Afolabi MO, 2016. Safety and immunogenicity of Chad63 and MVA ME-TRAP in west African children and infants. Mol Ther 24: 14701477. [Google Scholar]
  10. Mensah VA, MVVC Group , 2016. Safety, immunogenicity and efficacy of prime-boost vaccination with Chad63 and MVA encoding ME-TRAP against Plasmodium falciparum infection in adults in Senegal. PLoS One 11: e0167951. [Google Scholar]
  11. Mensah VA, 2017. Safety and immunogenicity of malaria vectored vaccines given with routine expanded program on immunization vaccines in Gambian infants and neonates: a randomized controlled trial. Front Immunol 8: 1551. [Google Scholar]
  12. Hoffman SL, 2010. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6: 97106. [Google Scholar]
  13. Epstein JE, 2011. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334: 475480. [Google Scholar]
  14. Seder RA, VRC 312 Study Team , 2013. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341: 13591365. [Google Scholar]
  15. Ishizuka AS, 2016. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22: 614623. [Google Scholar]
  16. Epstein JE, 2017. Protection against Plasmodium falciparum malaria by PfSPZ vaccine. JCI Insight 2: e89154. [Google Scholar]
  17. Lyke KE, 2017. Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci USA 114: 27112716. [Google Scholar]
  18. Sissoko MS, 2017. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis 17: 498509. [Google Scholar]
  19. Olotu A, 2018. Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of Plasmodium falciparum sporozoites vaccine for malaria in healthy Equatoguinean men. Am J Trop Med Hyg 98: 308318. [Google Scholar]
  20. Jongo SA, 2018. Safety, immunogenicity, and protective efficacy against controlled human malaria infection of Plasmodium falciparum sporozoite vaccine in Tanzanian adults. Am J Trop Med Hyg 99: 338349. [Google Scholar]
  21. Schofield L, Ferreira A, Altszuler R, Nussenzweig V, Nussenzweig RS, , 1987. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J Immunol 139: 20202025. [Google Scholar]
  22. Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF, , 1988. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 85: 573576. [Google Scholar]
  23. Doolan DL, Hoffman SL, , 2000. The complexity of protective immunity against liver-stage malaria. J Immunol 165: 14531462. [Google Scholar]
  24. Weiss WR, Jiang CG, , 2012. Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS One 7: e31247. [Google Scholar]
  25. Zaidi I, 2017. γδ T cells are required for the induction of sterile immunity during irradiated sporozoite vaccinations. J Immunol 199: 37813788. [Google Scholar]
  26. Hoffman SL, 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 11551164. [Google Scholar]
  27. Mordmuller B, 2017. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542: 445449. [Google Scholar]
  28. Simon AK, Hollander GA, McMichael A, , 2015. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci 282: 20143085. [Google Scholar]
  29. Shekalaghe S, 2014. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 91: 471480. [Google Scholar]
  30. Kamau E, Alemayehu S, Feghali KC, Saunders D, Ockenhouse CF, , 2013. Multiplex qPCR for detection and absolute quantification of malaria. PLoS One 8: e71539. [Google Scholar]
  31. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I, , 2015. Ultra-sensitive detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS Med 12: e1001788. [Google Scholar]
  32. Reller ME, Chen WH, Dalton J, Lichay MA, Dumler JS, , 2013. Multiplex 5′ nuclease quantitative real-time PCR for clinical diagnosis of malaria and species-level identification and epidemiologic evaluation of malaria-causing parasites, including Plasmodium knowlesi. J Clin Microbiol 51: 29312938. [Google Scholar]
  33. Atroosh WM, Al-Mekhlafi HM, Mahdy MA, Saif-Ali R, Al-Mekhlafi AM, Surin J, , 2011. Genetic diversity of Plasmodium falciparum isolates from Pahang, Malaysia based on MSP-1 and MSP-2 genes. Parasit Vectors 4: 233. [Google Scholar]
  34. Anderson TJ, Su XZ, Bockarie M, Lagog M, Day KP, , 1999. Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology 119: 113125. [Google Scholar]
  35. Roestenberg M, 2013. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 88: 513. [Google Scholar]
  36. Sheehy SH, 2013. Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLoS One 8: e65960. [Google Scholar]
  37. Hodgson SH, 2014. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol 5: 686. [Google Scholar]
  38. Gomez-Perez GP, 2015. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar J 14: 306. [Google Scholar]
  39. Mordmüller B, 2015. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J 14: 117. [Google Scholar]
  40. Bastiaens GJ, 2016. Safety, immunogenicity, and protective efficacy of intradermal immunization with aseptic, purified, cryopreserved Plasmodium falciparum sporozoites in volunteers under chloroquine prophylaxis: a randomized controlled trial. Am J Trop Med Hyg 94: 663673. [Google Scholar]
  41. Lell B, 2018. Impact of sickle cell trait and naturally acquired immunity on uncomplicated malaria after controlled human malaria infection in adults in Gabon. Am J Trop Med Hyg 98: 508515. [Google Scholar]
  42. Vekemans J, Ota MO, Wang EC, Kidd M, Borysiewicz LK, Whittle H, McAdam KP, Morgan G, Marchant A, , 2002. T cell responses to vaccines in infants: defective IFNgamma production after oral polio vaccination. Clin Exp Immunol 127: 495498. [Google Scholar]
  43. Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Whittle H, Lambert PH, McAdam KP, Siegrist CA, Marchant A, , 2004. Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults. Vaccine 22: 511519. [Google Scholar]
  44. Forsthuber T, Yip HC, Lehmann PV, , 1996. Induction of TH1 and TH2 immunity in neonatal mice. Science 271: 17281730. [Google Scholar]
  45. Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J, Audet S, Maldonado Y, Arvin AM, , 2001. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 184: 817826. [Google Scholar]
  46. Li L, Lee HH, Bell JJ, Gregg RK, Ellis JS, Gessner A, Zaghouani H, , 2004. IL-4 utilizes an alternative receptor to drive apoptosis of Th1 cells and skews neonatal immunity toward Th2. Immunity 20: 429440. [Google Scholar]
  47. Rose S, Lichtenheld M, Foote MR, Adkins B, , 2007. Murine neonatal CD4+ cells are poised for rapid Th2 effector-like function. J Immunol 178: 26672678. [Google Scholar]
  48. He XS, Holmes TH, Mahmood K, Kemble GW, Dekker CL, Arvin AM, Greenberg HB, , 2008. Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J Infect Dis 197: 803811. [Google Scholar]
  49. Butler NS, Schmidt NW, Harty JT, , 2010. Differential effector pathways regulate memory CD8 T cell immunity against Plasmodium berghei versus P. yoelii sporozoites. J Immunol 184: 25282538. [Google Scholar]

Data & Media loading...

Supplemental figures and tables

  • Received : 18 Oct 2018
  • Accepted : 10 Jan 2019
  • Published online : 15 Apr 2019

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error